32 citations
,
August 2019 in “Nature Communications” Chemotherapy causes permanent hair follicle damage by triggering stem cell loss.
278 citations
,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
April 2025 in “Journal of Pharma Insights and Research.” Females had more chemotherapy side effects than males, with many being preventable.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
3 citations
,
October 2018 in “Journal of cosmetic dermatology” Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
7 citations
,
January 2012 in “PubMed” Azelaic acid and finasteride can help preserve skin flaps after surgery by increasing BCL-2 protein and decreasing bax protein.
May 2020 in “JAAD case reports” Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
1 citations
,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
27 citations
,
March 2008 in “Cell stress & chaperones” Localized heat or specific injections can prevent chemotherapy-induced hair loss without affecting cancer treatment.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
15 citations
,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
2 citations
,
February 2025 in “Advanced Healthcare Materials” Perhexiline can effectively target ovarian cancer cells left after treatment.
December 2023 in “Journal of Thoracic Disease” Increased EGFR gene variations may predict chemotherapy outcomes in small cell lung cancer patients.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” VB1953 gel significantly reduced acne and resistant bacteria in patients who didn't respond to clindamycin.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
3 citations
,
March 2012 in “Actas Dermo-Sifiliográficas” An elderly man with skin amyloidosis and abnormal blood proteins was monitored without finding widespread disease after 18 months.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.